NASDAQ:ALIM Alimera Sciences - ALIM Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Alimera Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.65 -0.02 (-1.20%) (As of 03/17/2023 08:53 PM ET) Add Compare Share Share Today's Range$1.57▼$1.6850-Day Range$1.61▼$3.2552-Week Range$1.57▼$7.92Volume3,600 shsAverage Volume11,131 shsMarket Capitalization$11.55 millionP/E RatioN/ADividend YieldN/APrice Target$6.75 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Alimera Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside309.1% Upside$6.75 Price TargetShort InterestHealthy0.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.33) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.91 out of 5 starsMedical Sector662nd out of 983 stocksPharmaceutical Preparations Industry315th out of 480 stocks 3.3 Analyst's Opinion Consensus RatingAlimera Sciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.75, Alimera Sciences has a forecasted upside of 309.1% from its current price of $1.65.Amount of Analyst CoverageAlimera Sciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.41% of the float of Alimera Sciences has been sold short.Short Interest Ratio / Days to CoverAlimera Sciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Alimera Sciences has recently increased by 2.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlimera Sciences does not currently pay a dividend.Dividend GrowthAlimera Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALIM. Previous Next 2.4 News and Social Media Coverage News SentimentAlimera Sciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.36 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Alimera Sciences this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Alimera Sciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alimera Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders12.90% of the stock of Alimera Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 24.58% of the stock of Alimera Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Alimera Sciences are expected to grow in the coming year, from ($2.33) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alimera Sciences is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alimera Sciences is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Alimera Sciences (NASDAQ:ALIM) StockAlimera Sciences, Inc. engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion. Its products include ILUVIEN and NADPH Oxidase Inhibitors. The company was founded by Daniel C. Myers and David R. Holland on June 4, 2003 and is headquartered in Alpharetta, GA.Read More Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Stock News HeadlinesMarch 17, 2023 | marketwatch.comOcular Inflammation Treatment Market Growth and Forecast till 2028March 15, 2023 | americanbankingnews.comAlimera Sciences (NASDAQ:ALIM) Coverage Initiated at StockNews.comMarch 20, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.March 8, 2023 | marketwatch.comOcular Inflammation Treatment Market To Observer Consistent Development All through Forecast Period 2023-2030March 2, 2023 | marketwatch.com2023-2029 Retinal Vein Occlusion Market Size and Risks Factors Analysis | Survey Report by Absolute ReportsFebruary 27, 2023 | finance.yahoo.comAlimera Appoints Roger Sawhney, M.D. to Its Board of DirectorsFebruary 23, 2023 | marketwatch.comAge-related Macular Degeneration Market Size 2023 with Pre COVID-19 and Post COVID-19 Market Scenario and Forecast till 2025February 23, 2023 | markets.businessinsider.comH.C. Wainwright Reaffirms Their Buy Rating on Alimera (ALIM)March 20, 2023 | Behind the Markets (Ad)Buy THIS stock before Taiwan is attacked... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.February 22, 2023 | finance.yahoo.comAlimera Announces Submission of Marketing Authorization Application in Switzerland for ILUVIEN®February 21, 2023 | marketwatch.comDiabetic Retinopathy Market Size Global Research Report, 2023 - 2028February 20, 2023 | marketwatch.comGlobal Ocular Inflammation Treatment Market Technology advancement and Latest Research Report 2023-2028January 31, 2023 | marketwatch.comIntravitreal (IVT) Injectables Market : Global Market Growth, New Trends, COVID-19 Impact and Forecast 2023 To 2028January 30, 2023 | marketwatch.comDiabetic Retinopathy Market International Business Analysis, Development Outlook and Regional Strategies 2028January 13, 2023 | marketwatch.comWet Age Related Macular Degeneration (AMD) Market Detailed Analysis of Current Industry Figures with Forecasts Regional Outlook 2028January 9, 2023 | finance.yahoo.comAlimera Sciences Appoints Industry Veteran Russell L. Skibsted as Chief Financial OfficerJanuary 5, 2023 | marketwatch.comDiabetic Retinopathy Market 2023 : Recent Developments, Industry Trends and Investigation Growth Rate, and Forecast to 2028December 29, 2022 | finance.yahoo.comAlimera Sciences, Inc. (NASDAQ:ALIM) Q3 2022 Earnings Call TranscriptDecember 23, 2022 | msn.comLooking Into Alimera Sciences's Return On Capital EmployedDecember 12, 2022 | marketwatch.comWet Age Related Macular Degeneration (AMD) Market Provides an In-Depth Insight of Trends and Landscape Outlook 2022-2028December 8, 2022 | finance.yahoo.comAlimera Sciences Announces Agreement to Extend Amortization Date and Interest-Only Period on Loan AgreementNovember 29, 2022 | finance.yahoo.comAlimera Highlights Abstracts Regarding Consensus Among US Retina Specialists and Reduced Retinal Thickness Variability Leading to Improved Visual Outcomes Following ILUVIEN® AdministrationNovember 25, 2022 | finance.yahoo.com7 Stocks That Could Implode at Any MomentNovember 23, 2022 | businesswire.comGlobal Diabetic Retinopathy Market Report to 2027 - Featuring Bayer, Alimera Sciences, Novartis and Pfizer Among Others - ResearchAndMarkets.comNovember 16, 2022 | finance.yahoo.comAlimera Sciences Third Quarter 2022 Earnings: Misses ExpectationsNovember 15, 2022 | seekingalpha.comAlimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | finanznachrichten.deAlimera Sciences, Inc.: Alimera Sciences Announces Third Quarter 2022 Financial ResultsSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alimera Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address ALIM Company Calendar Last Earnings10/27/2021Today3/20/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALIM CUSIPN/A CIK1267602 Webwww.alimerasciences.com Phone(678) 990-5740Fax678-990-5744Employees145Year Founded2003Price Target and Rating Average Stock Price Forecast$6.75 High Stock Price Forecast$9.00 Low Stock Price Forecast$4.50 Forecasted Upside/Downside+309.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,370,000.00 Net Margins-34.10% Pretax Margin-34.10% Return on EquityN/A Return on Assets-36.97% Debt Debt-to-Equity RatioN/A Current Ratio0.88 Quick Ratio0.82 Sales & Book Value Annual Sales$54.06 million Price / Sales0.21 Cash FlowN/A Price / Cash FlowN/A Book Value($3.15) per share Price / Book-0.52Miscellaneous Outstanding Shares6,996,000Free Float6,094,000Market Cap$11.54 million OptionableOptionable Beta1.42 Social Links Key ExecutivesRichard S. EiswirthPresident, Chief Executive Officer & DirectorPhilip John AshmanCOO & SVP-Commercial Operations EuropeRussell L. SkibstedChief Financial Officer & Senior Vice PresidentChristopher S. VisickSecretary, Vice President & General CounselDavid DyerChief Retina SpecialistKey CompetitorsHillstream BioPharmaNASDAQ:HILSSonnet BioTherapeuticsNASDAQ:SONNGraybug VisionNASDAQ:GRAYPulmatrixNASDAQ:PULMLixte BiotechnologyNASDAQ:LIXTView All CompetitorsInstitutional OwnershipCaligan Partners LPBought 478,777 shares on 2/16/2023Ownership: 6.840%Millennium Management LLCBought 11,963 shares on 2/15/2023Ownership: 0.171%Susquehanna International Group LLPBought 33,775 shares on 2/14/2023Ownership: 0.483%Renaissance Technologies LLCSold 10,200 shares on 2/13/2023Ownership: 1.464%View All Institutional Transactions ALIM Stock - Frequently Asked Questions Should I buy or sell Alimera Sciences stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alimera Sciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" ALIM shares. View ALIM analyst ratings or view top-rated stocks. What is Alimera Sciences' stock price forecast for 2023? 2 analysts have issued 1 year target prices for Alimera Sciences' shares. Their ALIM share price forecasts range from $4.50 to $9.00. On average, they predict the company's stock price to reach $6.75 in the next twelve months. This suggests a possible upside of 309.1% from the stock's current price. View analysts price targets for ALIM or view top-rated stocks among Wall Street analysts. How have ALIM shares performed in 2023? Alimera Sciences' stock was trading at $2.71 on January 1st, 2023. Since then, ALIM shares have decreased by 39.1% and is now trading at $1.65. View the best growth stocks for 2023 here. When is Alimera Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our ALIM earnings forecast. How were Alimera Sciences' earnings last quarter? Alimera Sciences, Inc. (NASDAQ:ALIM) announced its quarterly earnings results on Wednesday, October, 27th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.52) by $0.08. The biopharmaceutical company earned $12.15 million during the quarter, compared to the consensus estimate of $12.30 million. During the same quarter last year, the firm posted ($0.12) EPS. When did Alimera Sciences' stock split? Shares of Alimera Sciences reverse split before market open on Friday, November 15th 2019. The 1-15 reverse split was announced on Thursday, November 7th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 14th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. What is Rick Eiswirth's approval rating as Alimera Sciences' CEO? 2 employees have rated Alimera Sciences Chief Executive Officer Rick Eiswirth on Glassdoor.com. Rick Eiswirth has an approval rating of 100% among the company's employees. This puts Rick Eiswirth in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Alimera Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alimera Sciences investors own include EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD), Amarin (AMRN), AngloGold Ashanti (AU), SSR Mining (SSRM), ADMA Biologics (ADMA) and Cellectar Biosciences (CLRB). What is Alimera Sciences' stock symbol? Alimera Sciences trades on the NASDAQ under the ticker symbol "ALIM." Who are Alimera Sciences' major shareholders? Alimera Sciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Caligan Partners LP (6.84%), Renaissance Technologies LLC (1.46%), Susquehanna International Group LLP (0.48%), Millennium Management LLC (0.17%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James R Largent, John Philip Jones, Philip Ashman, Richard S Eiswirth Jr and Stanley Morgan. View institutional ownership trends. How do I buy shares of Alimera Sciences? Shares of ALIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Alimera Sciences' stock price today? One share of ALIM stock can currently be purchased for approximately $1.65. How much money does Alimera Sciences make? Alimera Sciences (NASDAQ:ALIM) has a market capitalization of $11.54 million and generates $54.06 million in revenue each year. The biopharmaceutical company earns $-4,370,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis. How many employees does Alimera Sciences have? The company employs 145 workers across the globe. How can I contact Alimera Sciences? Alimera Sciences' mailing address is 6120 WINDWARD PARKWAY STE 290, ALPHARETTA GA, 30005. The official website for the company is www.alimerasciences.com. The biopharmaceutical company can be reached via phone at (678) 990-5740, via email at scottg@coreir.com, or via fax at 678-990-5744. This page (NASDAQ:ALIM) was last updated on 3/20/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.